Search

Your search keyword '"Genentech"' showing total 266 results
Start Over Descriptor "Genentech"
266 results on '"Genentech"'

3. Machine learning for comprehensive forecasting of Alzheimer’s Disease progression

Author

Fisher, Charles K, Smith, Aaron M, and Walsh, Jonathan R

Subjects
Information and Computing Sciences, Biological Sciences, Machine Learning, Aging, Brain Disorders, Acquired Cognitive Impairment, Neurodegenerative, Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD), Alzheimer's Disease, Dementia, Good Health and Well Being, Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Cognitive Dysfunction, Disease Progression, Female, Forecasting, Humans, Male, Middle Aged, Models, Statistical, Models, Theoretical, Neuropsychological Tests, Coalition Against Major Diseases, Abbott, Alliance for Aging Research, Alzheimer’s Association, Alzheimer’s Foundation of America, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Critical Path Institute, CHDI Foundation, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Forest Research Institute, Genentech, Inc., GlaxoSmithKline, Johnson & Johnson, National Health Council, Novartis Pharmaceuticals Corporation, Parkinson’s Action Network, Parkinson’s Disease Foundation, Pfizer, Inc., sanofi-aventis. Collaborating Organizations: Clinical Data Interchange Standards Consortium (CDISC), Ephibian, Metrum Institute.
Abstract

Most approaches to machine learning from electronic health data can only predict a single endpoint. The ability to simultaneously simulate dozens of patient characteristics is a crucial step towards personalized medicine for Alzheimer's Disease. Here, we use an unsupervised machine learning model called a Conditional Restricted Boltzmann Machine (CRBM) to simulate detailed patient trajectories. We use data comprising 18-month trajectories of 44 clinical variables from 1909 patients with Mild Cognitive Impairment or Alzheimer's Disease to train a model for personalized forecasting of disease progression. We simulate synthetic patient data including the evolution of each sub-component of cognitive exams, laboratory tests, and their associations with baseline clinical characteristics. Synthetic patient data generated by the CRBM accurately reflect the means, standard deviations, and correlations of each variable over time to the extent that synthetic data cannot be distinguished from actual data by a logistic regression. Moreover, our unsupervised model predicts changes in total ADAS-Cog scores with the same accuracy as specifically trained supervised models, additionally capturing the correlation structure in the components of ADAS-Cog, and identifies sub-components associated with word recall as predictive of progression.

Published
2019

11. Roche's TIGIT prospect fails another phase 3 lung cancer test.

Author

Taylor, Nick Paul

Subjects
NON-small-cell lung carcinoma, CLINICAL trials, LUNG cancer, OVERALL survival, CELL survival
Abstract

The phase 3 trial found adding TIGIT candidate tiragolumab to a checkpoint inhibitor had no effect on overall survival in non-small cell lung cancer. [ABSTRACT FROM AUTHOR]

Published
2024

20. Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin.

Author

Riggs, Arthur D

Subjects
BACTERIAL genes, HUMAN genes, DNA, RECOMBINANT DNA, MOLECULAR cloning
Abstract

In the mid- to late 1970s, recombinant deoxyribonucleic acid methods for cloning and expressing genes in E. coli were under intense development. The important question had become: Can humans design and chemically synthesize novel genes that function in bacteria? This question was answered in 1978 and in 1979 with the successful expression in E. coli of 2 mammalian hormones, first somatostatin and then human insulin. The successful production of human insulin in bacteria provided, for the first time, a practical, scalable source of human insulin and resulted in the approval, in 1982, of human insulin for the treatment of diabetics. In this short review, I give my personal view of how the making, cloning, and expressing of human insulin genes was accomplished by a team of scientists led by Keiichi Itakura, Herbert W. Boyer, and myself. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. The 100 Best Companies to Work For.

Author

Moskowitz, Milton, Levering, Robert, Bartulski, Erin, Frauenheim, Ed, Gupta, Shalene, Hackett, Robert, and Shanker, Deena

Subjects
BUSINESS enterprise ratings, EMPLOYEE attitudes, CORPORATE culture
Abstract

The article presents a list of the publication's ranking of the 100 best companies to work for. Topics include details on the effect of employee's attitudes toward their employers on companies' ratings; details on the role of management and executives in fostering relationships with employees; and mention of companies on the list such as Internet-related services corporation Google, financial planner Edward Jones, and supermarket chain Wegmans Food Markets.

Published
2015

23. Relay loses interest in SHP2 inhibitor after Genentech abandons collab.

Author

Waldron, James

Subjects
ANGIOKERATOMA corporis diffusum, THERAPEUTICS, TUMORS
Abstract

Three weeks after Roche's Genentech unit walked away from the SHP2 inhibitor pact, Relay has confirmed it won't be pushing ahead with a solo project. [ABSTRACT FROM AUTHOR]

Published
2024

25. Sangamo secures $50M upfront in neurodegenerative pact with Roche's Genentech.

Author

Masson, Gabrielle

Subjects
ALZHEIMER'S disease, NEURODEGENERATION, GENE therapy, CELLULAR therapy, THERAPEUTICS
Abstract

Sangamo Therapeutics has secured a $2 billion-plus pact with Genentech to develop intravenous genomic medicines for neurodegenerative diseases. [ABSTRACT FROM AUTHOR]

Published
2024

26. FDA Approves Genentech's Vabysmo Prefilled Syringe PFS for Three Leading Causes of Vision Loss.

Abstract

The FDA has approved Genentech's Vabysmo Prefilled Syringe PFS for three leading causes of vision loss. However, there are potential side effects associated with the use of Vabysmo, including an increase in eye pressure, blood clots, and retinal vascular occlusion. Common adverse reactions include cataracts and conjunctival hemorrhage. It is important for healthcare providers to monitor patients for these events and for patients to report any changes in vision. Additionally, there may be potential risks to unborn babies and breastfeeding infants, so patients should use birth control and consult with their healthcare provider. Genentech is a biotechnology company that focuses on developing treatments for eye diseases. [Extracted from the article]

Published
2024

27. Genentech sinks SHP2 pact, leaving Relay to race thinning field.

Author

Taylor, Nick Paul

Subjects
RELAY racing, REPATRIATION
Abstract

Genentech has scuttled its SHP2 inhibitor pact, returning the rights to Relay Therapeutics after plowing more than $120 million into the alliance. [ABSTRACT FROM AUTHOR]

Published
2024

28. Using Stock and Stock Options to Minimize Patent Royalty Payment Risks after Medimmune v. Genentech

Author

O'Connor, Sean

Subjects
licensing, MedImmune, Genentech, running royalties, tech transfer, patents, universities, start-ups, spin-offs
Abstract

The Supreme Court’s recent decision in MedImmune v. Genentech left patent owners who license out their patents in exchange for royalty streams in a bad spot. It is an especially dire spot for patent owners such as universities who incur substantial opportunity costs when they grant an exclusive license to a licensee who pays relatively little up front, in exchange for paying a potentially sizable royalty stream if or when products based on the patents are successfully commercialized and sold in the marketplace. Because the MedImmune decision allows such licensees to bring declaratory judgment actions to invalidate the patent or establish the licensee’s products as non-infringing with no particular trigger and without repudiating the licensee (and thus avoiding the possibility of a patent owner suit for infringement), it is expected that licensees will take a license just to buy time to develop a product with relative freedom to operate and then attempt to invalidate the patent once a product looks like it will become profitable and royalties would have to be paid. While some have suggested that the solution to this is simply for patent owners to demand full payment of the net present value of the royalty stream up front, this will simply not be possible for many start up and mid sized companies who license technologies from universities and other routine licensors. The author instead proposes a method for licensors to take some combination of stock and stock options in the licensee – that essentially the licensee can “afford” to pay in the near term even while short on cash and revenues – while still allowing the licensor to participate in the potential upside of a successful commercialization effort of the licensor’s patents by the licensee, but in a manner that is fully accrued to the licensor upon the execution of the license.

Published
2007

32. Roche's Genentech spends $15M to rocket into GenEdit's NanoGalaxy.

Author

Bayer, Max

Subjects
AUTOIMMUNE diseases, GENE therapy, NANOPARTICLES
Abstract

GenEdit and Genentech are partnering to develop polymer nanoparticles to enhance the delivery of gene-editing therapies for autoimmune diseases. [ABSTRACT FROM AUTHOR]

Published
2024

38. Enabling drug discovery project decisions with integrated computational chemistry and informatics.

Author

Tsui, Vickie, Ortwine, Daniel, and Blaney, Jeffrey

Subjects
*COMPUTATIONAL chemistry, *CHEMISTRY, *COMPUTERS, *SOFTWARE engineering, *WORK environment, *CHEMINFORMATICS
Abstract

Computational chemistry/informatics scientists and software engineers in Genentech Small Molecule Drug Discovery collaborate with experimental scientists in a therapeutic project-centric environment. Our mission is to enable and improve pre-clinical drug discovery design and decisions. Our goal is to deliver timely data, analysis, and modeling to our therapeutic project teams using best-in-class software tools. We describe our strategy, the organization of our group, and our approaches to reach this goal. We conclude with a summary of the interdisciplinary skills required for computational scientists and recommendations for their training. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

39. Making, Cloning, and the Expression of Human Insulin Genes in Bacteria: The Path to Humulin

Author

Arthur D. Riggs

Subjects
0301 basic medicine, Endocrinology, Diabetes and Metabolism, DNA, Recombinant, Reviews, 030209 endocrinology & metabolism, Biology, law.invention, recombinant DNA, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, law, Insulin, Regular, Human, Escherichia coli, Humans, Insulin, Cloning, Molecular, Gene, Cloning, Genetics, chemical DNA synthesis, biology.organism_classification, 030104 developmental biology, Somatostatin, chemistry, Recombinant DNA, genentech, AcademicSubjects/MED00250, Function (biology), DNA, Bacteria, biotechnology, Hormone
Abstract

In the mid- to late 1970s, recombinant deoxyribonucleic acid methods for cloning and expressing genes in E. coli were under intense development. The important question had become: Can humans design and chemically synthesize novel genes that function in bacteria? This question was answered in 1978 and in 1979 with the successful expression in E. coli of 2 mammalian hormones, first somatostatin and then human insulin. The successful production of human insulin in bacteria provided, for the first time, a practical, scalable source of human insulin and resulted in the approval, in 1982, of human insulin for the treatment of diabetics. In this short review, I give my personal view of how the making, cloning, and expressing of human insulin genes was accomplished by a team of scientists led by Keiichi Itakura, Herbert W. Boyer, and myself., Graphical Abstract Graphical Abstract

Published
2020
Full Text
View/download PDF

40. InnovationRx: Generative AI For Drug Discovery.

Author

Jennings, Katie

Subjects
DRUG discovery, ARTIFICIAL intelligence
Abstract

InnovationRx is your weekly digest of healthcare news. Sign up! [ABSTRACT FROM AUTHOR]

Published
2023

44. Chutes & Ladders—Longtime BioMarin CEO hands baton off to Genentech chief.

Author

Bayer, Max, Masson, Gabrielle, and Armstrong, Annalee

Subjects
CHIEF executive officers, CHIEF financial officers
Abstract

Longtime BioMarin CEO hands baton off to Genentech chief. J&J's cancer R&D chief to retire. Viridian taps ex-Magenta CFO for chief executive job. [ABSTRACT FROM AUTHOR]

Published
2023

45. ESMO: Roche still hanging on for TIGIT roller coaster ride.

Author

Armstrong, Annalee

Subjects
DRUG development, ANTINEOPLASTIC agents
Abstract

Roche's commitment to the TIGIT class has paid off, says Charlie Fuchs, global head of oncology and hematology drug development. [ABSTRACT FROM AUTHOR]

Published
2023

49. Chutes & Ladders—3 Flagship-backed biotechs make key exec hires.

Author

Bayer, Max and Masson, Gabrielle

Subjects
CHIEF executive officers, PROGRAMMABLE controllers, GENES
Abstract

Three Flagship companies make key exec hires. Ex-Novartis cell and gene head to be new Resolution CEO. Cidara names translational science head. [ABSTRACT FROM AUTHOR]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results